MarmagkiolisKHakeemAChoksiN, et al. 12-month primary patency rates of contemporary endovascular device therapy for femoro-popliteal occlusive disease in 6,024 patients: beyond balloon angioplasty. Catheter Cardiovasc Interv. 2014;84:555–564.
2.
SogaYIidaOHiranoK, et al. Mid-term clinical outcome and predictors of vessel patency after femoropopliteal stenting with self-expandable nitinol stent. J Vasc Surg. 2010;52:608–615.
3.
IidaOTakaharaMSogaY, et al. The characteristics of in-stent restenosis after drug-eluting stent implantation in femoropopliteal lesions and 1-year prognosis after repeat endovascular therapy for these lesions. JACC Cardiovasc Interv. 2016;9:828–834.
4.
IidaOUematsuMSogaY, et al. Timing of the restenosis following nitinol stenting in the superficial femoral artery and the factors associated with early and late restenoses. Catheter Cardiovasc Interv. 2011;78:611–617.
5.
DakeMDAnselGMJaffMR, et al. Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery: 5-year results of the Zilver PTX randomized trial. Circulation. 2016;133:1472–1483.
6.
AxelDIKunertWGoggelmannC, et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation. 1997;96:636–645.
7.
WiskirchenJSchoberWSchartN, et al. The effects of paclitaxel on the three phases of restenosis: smooth muscle cell proliferation, migration, and matrix formation: an in vitro study. Invest Radiol. 2004;39:565–571.
8.
Müller-HülsbeckSKeirseKZellerT, et al. Twelve-month results from the MAJESTIC trial of the Eluvia paclitaxel-eluting stent for treatment of obstructive femoropopliteal disease. J Endovasc Ther. 2016;23:701–707.
9.
IidaOTakaharaMSogaY, et al. 1-Year results of the ZEPHYR Registry (Zilver PTX for the Femoral Artery and Proximal Popliteal Artery): predictors of restenosis. JACC Cardiovasc Interv. 2015;8:1105–1112.
10.
SogaYIidaOHiranoK, et al. Utility of new classification based on clinical and lesional factors after self-expandable nitinol stenting in the superficial femoral artery. J Vasc Surg. 2011;54:1058–1066.
11.
SogaYTakaharaMIidaO, et al. Relationship between primary patency and lesion length following bare nitinol stent placement for femoropopliteal disease. J Endovasc Ther. 2015;22:862–867.
12.
FanelliFCannavaleAGazzettiM, et al. Calcium burden assessment and impact on drug-eluting balloons in peripheral arterial disease. Cardiovasc Intervent Radiol. 2014;37:898–907.
13.
SchmidtAPiorkowskiMGörnerH, et al. Drug-coated balloons for complex femoropopliteal lesions: 2-year results of a real-world registry. JACC Cardiovasc Interv. 2016;9:715–724.
14.
GrottiSLiistroFAngioliP, et al. Paclitaxel-eluting balloon vs standard angioplasty to reduce restenosis in diabetic patients with in-stent restenosis of the superficial femoral and proximal popliteal arteries: three-year results of the DEBATE-ISR study. J Endovasc Ther. 2016;23:52–57.
